1[1]Brasel K, Escobar S, Anderberg R, et al. Expression of the fit3 receptor and its ligand on hematopoietic cells. Leukemia, 1995,9(7): 1212 ～ 1218.
2[2]Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia, 1996,10(4) :588 ～ 599.
3[3]Drexler HG, Meyer C, Quentmeier H. Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells. Leuk Lymphoma, 1999, 33(12) :83 ～91.
4[4]Mizuki M, Fenski R, Halfter H, et al. FLT3 mutations from patients with acute myeloid leukemia induce transformation of 32D ceils mediated by the Ras and STAT5 pathways. Blood, 2000,96(12) :3907 ～ 3914.
5[5]Kottaridis PD, Gale RE, Frew ME. The presence of a FLT3 internal tandem duplication in patients with acute myeloidleukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 2001,98(6): 1752 ～ 1759.
6[6]Moreno I, Martin G, Bolufer P, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.Haematologica, 2003,88(1 ): 19 ～ 24.
7[7]Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 2001,97(8) :2434 ～ 2439.
8[8]Meshinchi S, Stirewalt DL, Alonzo TA, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood, 2003,102(4): 1474 ～ 1479.
9[9]Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FABsubtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 2002, 100( 1 ): 59 ～ 66.
10[10]Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood, 2002, 100(7) :2393 ～ 2398.
